Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan

被引：0
|
作者：
Xiuting Mo
Kensuke Moriwaki
Kosuke Morimoto
Kojiro Shimozuma
机构：
[1] Ritsumeikan University,Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology
[2] Kyoto University,Graduate School of Medicine
[3] Ritsumeikan University,Division of Health Services Research, Department of Biomedical Sciences, College of Life Sciences
[4] Ritsumeikan University,Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology
来源：
Clinical Drug Investigation | 2022年 / 42卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：599 / 609
页数：10
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS OF TREMELIMUMAB AS FIRST-LINE THERAPY FOR METASTATIC NON-SMALL CELL LUNG CANCER IN JAPAN
    Sakai, R.
    Moriwaki, K.
    Morimoto, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2024, 27 (06) : S150 - S150
  • [42] Nivolumab plus ipilimumab as first-line treatment for patients with advanced non-small cell lung cancer: A systematic review
    Tandiono, J.
    Chen, S.
    Marcella, E.
    Susanto, B.
    Heriyanto, R. S.
    Wijovi, F.
    Tancherla, A.
    Kurniawan, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S759 - S760
  • [43] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECE
    Diamantogiannis, F.
    Viktoratos, P.
    May, J.
    Malcolm, B.
    Van de Wetering, G.
    Ignacio, T.
    VALUE IN HEALTH, 2019, 22 : S468 - S469
  • [44] EXPANDING THE HTA COST-EFFECTIVENESS ANALYSES FOR CHECKMATE 9LA: NIVOLUMAB PLUS IPILIMUMAB PLUS CHEMOTHERAPY AS FIRST-LINE STRATEGY FOR NON-SMALL CELL LUNG CANCER
    Orsini, I
    Venkatachalam, M.
    Yuan, Y.
    Lee, A.
    Penrod, J. R.
    VALUE IN HEALTH, 2023, 26 (12) : S322 - S322
  • [45] Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer
    Shen Lin
    Shaohong Luo
    Lixian Zhong
    Shubin Lai
    Dayong Zeng
    Xin Rao
    Pinfang Huang
    Xiuhua Weng
    International Journal of Clinical Pharmacy, 2020, 42 : 1175 - 1183
  • [46] Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer
    C C Earle
    W K Evans
    British Journal of Cancer, 1999, 80 : 815 - 820
  • [47] Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Wielage, Ron
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Lawson, Anthony
    Schwartzberg, Lee
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (08) : 1263 - 1272
  • [48] Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer
    Lin, Shen
    Luo, Shaohong
    Zhong, Lixian
    Lai, Shubin
    Zeng, Dayong
    Rao, Xin
    Huang, Pinfang
    Weng, Xiuhua
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (04) : 1175 - 1183
  • [49] Oxaliplatin in First-line Therapy for Advanced Non-Small-Cell Lung Cancer
    Raez, Luis E.
    Kobina, Svetlana
    Santos, Edgardo S.
    CLINICAL LUNG CANCER, 2010, 11 (01) : 18 - 24
  • [50] Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer
    Earle, CC
    Evans, WK
    BRITISH JOURNAL OF CANCER, 1999, 80 (5-6) : 815 - 820
12345